DrugPatentWatch Database Preview
Drugs in Development Information for Tivozanib
» See Plans and Pricing
What is the development status for investigational drug Tivozanib?
Tivozanib is an investigational drug.
There have been 32 clinical trials for Tivozanib.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2010.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Renal Cell, and Colorectal Neoplasms. The leading clinical trial sponsors are AVEO Pharmaceuticals, Inc., National Comprehensive Cancer Network, and National Cancer Institute (NCI).
Summary for Tivozanib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,259 |
| WIPO Patent Applications | 1,038 |
| Japanese Patent Applications | 406 |
| Clinical Trial Progress | Phase 3 (2010-03-01) |
| Vendors | 81 |
Recent Clinical Trials for Tivozanib
| Title | Sponsor | Phase |
|---|---|---|
| Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| A Study of Tivozanib in Combination With Durvalumab in Subjects With Untreated Advanced Hepatocellular Carcinoma | AstraZeneca | Phase 1/Phase 2 |
| A Study of Tivozanib in Combination With Durvalumab in Subjects With Untreated Advanced Hepatocellular Carcinoma | AVEO Pharmaceuticals, Inc. | Phase 1/Phase 2 |
Clinical Trial Summary for Tivozanib
Top disease conditions for Tivozanib
Top clinical trial sponsors for Tivozanib
US Patents for Tivozanib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
